Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have received an average recommendation of “Buy” from the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have covered the stock in the […]
Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price objective upped by Wells Fargo & Company from $17.00 to $22.00 in a research report released on Tuesday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biotechnology company’s stock. Other research analysts have also issued research reports about the stock. […]
Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price target increased by Wells Fargo & Company from $17.00 to $22.00 in a research report report published on Tuesday, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biotechnology company’s stock. IOVA has been the topic of a number of other research […]
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted.